Matt D. Galsky
YOU?
Author Swipe
View article: Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma Open
Along with previously published safety data, EV+P demonstrated benefit compared with chemotherapy across all prespecified subgroups, consistent with the ITT population and supporting EV+P as the standard of care for first-line treatment of…
View article: Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC).
Patterns of chemotherapy administration in bladder preservation therapy (BPT) for muscle-invasive bladder cancer (MIBC). Open
Background: Trimodality bladder preservation therapy (BPT) in muscle invasive bladder cancer (MIBC) includes a maximal transurethral resection followed by concurrent chemoradiotherapy as an alternative to radical cystectomy (RC) in appropr…
View article: 28P 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
28P 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms Open
CheckMate 274 met the primary endpoints of improved disease-free survival (DFS) with nivolumab (NIVO) v placebo (PBO) both in the intent-to-treat (ITT) population and in patients (pts) with programmed death-ligand 1 (PD-L1) expression ≥1% …
View article: LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial
LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial Open
View article: 1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)
1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001) Open
View article: Perioperative pembrolizumab or pembrolizumab + enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer: Phase 3 KEYNOTE-905/EV-303 study
Perioperative pembrolizumab or pembrolizumab + enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer: Phase 3 KEYNOTE-905/EV-303 study Open
View article: Updated Overall Survival (OS) with atezolizumab (atezo) monotherapy vs. chemotherapy in untreated locally advanced or metastatic Urothelial Carcinoma (mUC) in the Phase III IMvigor130 study
Updated Overall Survival (OS) with atezolizumab (atezo) monotherapy vs. chemotherapy in untreated locally advanced or metastatic Urothelial Carcinoma (mUC) in the Phase III IMvigor130 study Open
View article: Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data
Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data Open
View article: Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial
Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial Open
View article: The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials
The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials Open
View article: LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)
LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS) Open
View article: 798TiP Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
798TiP Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer Open
View article: Does androgen deprivation therapy protect against severe complications from COVID-19?
Does androgen deprivation therapy protect against severe complications from COVID-19? Open
View article: 20-year follow-up of the 1995-1996 Stockholm bladder cancer project
20-year follow-up of the 1995-1996 Stockholm bladder cancer project Open
View article: Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: Results from the national cancer database
Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: Results from the national cancer database Open
View article: ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer
ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer Open
Immune checkpoint inhibitors have revolutionized the treatment of patients with metastatic urothelial carcinoma. In cisplatin-eligible muscle-invasive bladder cancer (MIBC), cisplatin-based neoadjuvant chemotherapy (NAC) before radical cys…
View article: Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours
Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours Open
View article: cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC) Open
View article: IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) Open
View article: Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1
Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1 Open
View article: PD67-08 IDENTIFYING FACTORS ASSOCIATED WITH POOR GENITOURINARY CANCER CLINICAL TRIAL ACCRUAL USING A NOVEL DATA EXTRACTION ALGORITHM
PD67-08 IDENTIFYING FACTORS ASSOCIATED WITH POOR GENITOURINARY CANCER CLINICAL TRIAL ACCRUAL USING A NOVEL DATA EXTRACTION ALGORITHM Open
You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Value of Care: Cost and Outcomes Measures II (PD67)1 Apr 2019PD67-08 IDENTIFYING FACTORS ASSOCIATED WITH POOR GENITOURINARY CANCER CLINICAL TRIAL ACCRUAL U…
View article: JAVELIN PARP medley: A phase Ib/II study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors
JAVELIN PARP medley: A phase Ib/II study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors Open
Background: Avelumab, a human anti–PD-L1 IgG1 monoclonal antibody, is approved for the treatment of metastatic Merkel cell carcinoma in various countries and advanced urothelial carcinoma after progression on platinum therapy in the United…
View article: A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer
A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer Open
Background: DS-8201a is a novel antibody-drug conjugate comprised of a humanized HER2 antibody attached by a cleavable peptide-based linker to a topoisomerase I inhibitor; characterized by a high drug-to-antibody ratio of about 8. In an on…
View article: Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)
Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC) Open
Background: mUC arising from UTUC vs LTUC may involve distinct biology resulting in different treatment responses & outcomes. However, this hypothesis has not been comprehensively explored. Here, data from 2 prospective trials of atezo (an…
View article: Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors
Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors Open
Background: DNA damage caused by TMZ can sensitize tumors to the effects of PARP inhibitors. Pamiparib is a selective PARP1/2 inhibitor with potent PARP trapping that can cross the blood-brain barrier and has shown synergistic cytotoxicity…
View article: MP18-04 MULTIMODAL TREATMENT WITH CHEMOTHERAPY AND RADICAL NEPHROURETERECTOMY MAY IMPROVE OVERALL SURVIVAL IN PATIENTS WITH CLINICALLY POSITIVE LYMPH NODE DISEASE
MP18-04 MULTIMODAL TREATMENT WITH CHEMOTHERAPY AND RADICAL NEPHROURETERECTOMY MAY IMPROVE OVERALL SURVIVAL IN PATIENTS WITH CLINICALLY POSITIVE LYMPH NODE DISEASE Open
You have accessJournal of UrologyBladder Cancer: Upper Tract Transitional Cell Carcinoma I1 Apr 2018MP18-04 MULTIMODAL TREATMENT WITH CHEMOTHERAPY AND RADICAL NEPHROURETERECTOMY MAY IMPROVE OVERALL SURVIVAL IN PATIENTS WITH CLINICALLY POSI…
View article: 285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)
285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC) Open
View article: Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study
Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study Open
View article: Supplementary Material for: Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors
Supplementary Material for: Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors Open
Objective: LY2603618, a selective inhibitor of checkpoint kinase 1 (CHK1) and key regulator of the DNA damage checkpoint, may enhance the effects of antimetabolites. This phase I study defined the recommended phase II dose of LY2603…